Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease

Experimental Biology and Medicine

Volumn 241, Issue 15, 2016, Pages 1676-1683

  Salameh, Therese S ^a,b   Rhea, Elizabeth M ^a,b   Banks, William A ^a,b   Hanson, Angela J ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; apolipoprotein E; cognition; dyslipidemia; insulin resistance

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CHOLESTEROL; CYCLOPHILIN A; DYNORPHIN; GALANIN; GALANIN LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INSULIN; OREXIN; PHOSPHOLIPID; PRESENILIN 1; PRESENILIN 2; TRIACYLGLYCEROL;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID-TO-PLASMA RATIO; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DYSLIPIDEMIA; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; PROTEIN INTERACTION; COGNITIVE DYSFUNCTION; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; COGNITIVE DYSFUNCTION; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE;

EID: 84983339463     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370216660770     Document Type: Article

References (106)

1. E.B.Lee. Obesity, leptin, and Alzheimer's disease. Ann N Y Acad Sci2011; 1243: 15–29.
2. C.C.LiuT.KanekiyoH.XuG.Bu. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol2013; 9: 106–18.
3. R.A.SperlingP.S.AisenL.A.BeckettD.A.BennettS.CraftA.M.FaganT.IwatsuboC.R.JackJr.J.KayeT.J.MontineD.C.ParkE.M.ReimanC.C.RoweE.SiemersY.SternK.YaffeM.C.CarrilloB.ThiesM.Morrison-BogoradM.V.WagsterC.H.Phelps. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers & Dement2011; 7: 280–92.
4. C.PaquetJ.AminF.Mouton-LigerM.NasserS.LoveF.GrayR.M.PickeringJ.A.R.NicollC.HolmesJ.HugonD.Boche. Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease. J Pathol2015; 235: 721–30.
5. M.EwersG.B.FrisoniS.J.TeipelL.T.GrinbergE.AmaroJrH.HeinsenP.M.ThompsonH.Hampel. Staging Alzheimer's disease progression with multimodality neuroimaging. Prog Neurobiol2011; 95: 535–46.
6. D.J.Selkoe. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev2001; 81: 741–66.
7. N.DemeesterG.CastroC.DesrumauxC.De GeitereJ.C.FruchartP.SantensE.MullenersS.EngelborghsP.P.De DeynJ.VandekerckhoveM.RosseneuC.Labeur. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin: cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J Lipid Res2000; 41: 963–74.
8. R.D.BellB.V.Zlokovic. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol2009; 118: 103–13.
9. M.A.EricksonM.L.NiehoffS.A.FarrJ.E.MorleyL.A.DillmanK.M.LynchW.A.Banks. Peripheral administration of antisense oligonucleotides targeting the amyloid-beta protein precursor reverses AbetaPP and LRP-1 overexpression in the aged SAMP8 mouse brain. J Alzheimers Dis2012; 28: 951–60.
10. J.FanJ.DonkinC.Wellington. Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E. Biofactors2009; 35: 239–48.
11. J.KimJ.M.BasakD.M.Holtzman. The role of apolipoprotein E in Alzheimer's disease. Neuron2009; 63: 287–303.
12. R.D.BellE.A.WinklerI.SinghA.P.SagareR.DeaneZ.WuD.M.HoltzmanC.BetsholtzA.ArmulikJ.SallstromB.C.BerkB.V.Zlokovic. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature2012; 485: 512–6.
13. S.M.FullertonG.A.ShirmanW.J.StrittmatterW.D.Matthew. Impairment of the blood-nerve and blood-brain barriers in apolipoprotein E knockout mice. Exp Neurol2001; 169: 13–22.
14. J.E.DonahueC.E.Johanson. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol2008; 67: 261–70.
15. M.A.EricksonW.A.Banks. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab2013; 33: 1500–13.
16. M.C.Phillips. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life2014; 66: 616–23.
17. R.W.MahleyY.Huang. Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron2012; 76: 871–85.
18. C.A.HawkesP.M.SullivanS.HandsR.O.WellerJ.A.R.NicollR.O.Carare. Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ɛ4 allele. PLoS One2012; 7: e41636–e41636.
19. A.G.YipA.C.McKeeR.C.GreenJ.WellsH.YoungL.A.CupplesL.A.Farrer. APOE, vascular pathology, and the AD brain. Neurology2005; 65: 259–65.
20. D.R.PremkumarD.L.CohenP.HederaR.P.FriedlandR.N.Kalaria. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol1996; 148: 2083–95.
21. S.SallowayT.GurT.BerzinR.TavaresB.ZipserS.CorreiaV.HovanesianJ.FallonV.Kuo-LeblancD.GlassC.HuletteC.RosenbergM.VitekE.Stopa. Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease. J Neurol Sci2002; 203–204: 183–7.
22. B.V.Zlokovic. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol2013; 70: 440–4.
23. K.NishitsujiT.HosonoT.NakamuraG.BuM.Michikawa. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J Biol Chem2011; 286: 17536–42.
24. R.DeaneA.SagareK.HammM.ParisiS.LaneM.B.FinnD.M.HoltzmanB.V.Zlokovic. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest2008; 118: 4002–13.
25. A.M.BennetE.Di AngelantonioZ.YeF.WensleyA.DahlinA.AhlbomB.KeavneyR.CollinsB.WimanU.de FaireJ.Danesh. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA2007; 298: 1300–11.
26. R.J.Caselli. Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?Pediat Blood Cancer2013; 10: 1739–42.
27. B.CholertonL.D.BakerS.Craft. Insulin resistance and pathological brain ageing. DiabMed2011; 28: 1463–75.
28. S.M.de la Monte. Relationships between diabetes and cognitive impairment. Endocrinol Metabol Clin North Am2014; 43: 245–67.
29. E.BlazquezE.Velázquez SánchezV.Hurtado-CarneiroJ.M.Ruiz Albusac. Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front Endocrinol2014; 5: 1–21.
30. A.OttR.P.StolkF.van HarskampH.A.PolsA.HofmanM.M.Breteler. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology1999; 53: 1937–42.
31. P.NewsholmeV.CruzatF.ArfusoK.Keane. Nutrient regulation of insulin secretion and action. J Endocrinol2014; 221: R105–20.
32. C.J.NolanM.S.MadirajuV.Delghingaro-AugustoM.L.PeyotM.Prentki. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes2006; 55(Suppl 2): S16–23.
33. E.L.GoldbergV.D.Dixit. Drivers of age-related inflammation and strategies for healthspan extension. Immunol Rev2015; 265: 63–74.
34. M.T.HenekaM.J.CarsonJ.El KhouryG.E.LandrethF.BrosseronD.L.FeinsteinA.H.JacobsT.Wyss-CorayJ.VitoricaR.M.RansohoffK.HerrupS.A.FrautschyB.FinsenG.C.BrownA.VerkhratskyK.YamanakaJ.KoistinahoE.LatzA.HalleG.C.PetzoldT.TownD.MorganM.L.ShinoharaV.H.PerryC.HolmesN.G.BazanD.J.BrooksS.HunotB.JosephN.DeigendeschO.GaraschukE.BoddekeC.A.DinarelloJ.C.BreitnerG.M.ColeD.T.GolenbockM.P.Kummer. Neuroinflammation in Alzheimer's disease. Lancet Neurol2015; 14: 388–405.
35. R.GhasemiA.HaeriL.DargahiZ.MohamedA.Ahmadiani. Insulin in the brain: sources, localization and functions. Mol Neurobiol2013; 47: 145–71.
36. D.PorteJr.R.J.SeeleyS.C.WoodsD.G.BaskinD.P.FiglewiczM.W.Schwartz. Obesity, diabetes and the central nervous system. Diabetologia1998; 41: 863–81.
37. H.J.ArmbrechtA.M.SiddiquiM.GreenS.A.FarrV.B.KumarW.A.BanksP.PatrickG.N.ShahJ.E.Morley. Antisense against amyloid-beta protein precursor reverses memory deficits and alters gene expression in neurotropic and insulin-signaling pathways in SAMP8 mice. J Alzheimers Dis2015; 46: 535–48.
38. J.FreiherrM.HallschmidW.H.Frey2ndY.F.BrunnerC.D.ChapmanC.HolscherS.CraftF.G.De FeliceC.Benedict. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs2013; 27: 505–14.
39. W.A.BanksJ.B.JaspanA.J.Kastin. Effect of diabetes mellitus on the permeability of the blood-brain barrier to insulin. Peptides1997; 18: 1577–84.
40. E.J.RiveraA.GoldinN.FulmerR.TavaresJ.R.WandsS.M.de la Monte. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis2005; 8: 247–68.
41. Y.LiuF.LiuI.Grundke-IqbalK.IqbalC.X.Gong. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol2011; 225: 54–62.
42. E.SteenB.M.TerryE.J.RiveraJ.L.CannonT.R.NeelyR.TavaresX.J.XuJ.R.WandsS.M.de la Monte. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes?J Alzheimers Dis2005; 7(1): 63–80.
43. A.RickleN.BogdanovicI.VolkmanB.WinbladR.RavidR.F.Cowburn. Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport2004; 15: 955–9.
44. K.TalbotH.Y.WangH.KaziL.Y.HanK.P.BakshiA.StuckyR.L.FuinoK.R.KawaguchiA.J.SamoyednyR.S.WilsonZ.ArvanitakisJ.A.SchneiderB.A.WolfD.A.BennettJ.Q.TrojanowskiS.E.Arnold. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest2012; 122: 1316–38.
45. S.CraftE.PeskindM.W.SchwartzG.D.SchellenbergM.RaskindD.PorteJr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology1998; 50: 164–8.
46. R.GhasemiL.DargahiA.HaeriM.MoosaviZ.MohamedA.Ahmadiani. Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders. Mol Neurobiol2013; 47: 1045–65.
47. J.J.LochheadR.G.Thorne. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev2012; 64: 614–28.
48. M.E.MeredithT.SalamehW.Banks. Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases. AAPS J2015; 17: 780–7.
49. K.ShibaH.KageyamaF.TakenoyaS.Shioda. Galanin-like peptide and the regulation of feeding behavior and energy metabolism. FEBS J2010; 277: 5006–13.
50. S.ShiodaH.KageyamaF.TakenoyaK.Shiba. Galanin-like peptide: a key player in the homeostatic regulation of feeding and energy metabolism?Int J Obes2011; 35: 619–28.
51. F.M.AminA.HougaardH.W.SchytzM.S.AsgharE.LundholmA.I.ParvaizP.J.H.de KoningM.R.AndersenH.B.W.LarssonJ.FahrenkrugJ.OlesenM.Ashina. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain2014; 137: 779–94.
52. J.KinhultM.AdnerR.UddmanL.O.Cardell. Pituitary adenylate cyclase-activating polypeptide, effects in the human nose. Clin Exp Allerg2003; 33: 942–9.
53. H.UenoM.MizutaT.ShiiyaW.TsuchimochiK.NomaN.NakashimaM.FujiharaM.Nakazato. Exploratory trial of intranasal administration of glucagon-like peptide-1 in Japanese patients with type 2 diabetes. Diab Care2014; 37: 2024–7.
54. S.CraftL.D.BakerT.J.MontineS.MinoshimaG.S.WatsonA.ClaxtonM.ArbuckleM.CallaghanE.TsaiS.R.PlymateP.S.GreenJ.LeverenzD.CrossB.Gerton. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol2012; 69: 29–38.
55. M.A.RegerG.S.WatsonW.H.Frey2ndL.D.BakerB.CholertonM.L.KeelingD.A.BelongiaM.A.FishelS.R.PlymateG.D.SchellenbergM.M.CherrierS.Craft. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging2006; 27: 451–8.
56. M.A.RegerG.S.WatsonP.S.GreenC.W.WilkinsonL.D.BakerB.CholertonM.A.FishelS.R.PlymateJ.C.BreitnerW.DeGroodtP.MehtaS.Craft. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology2008; 70: 440–8.
57. C.BenedictM.HallschmidA.HatkeB.SchultesH.L.FehmJ.BornW.Kern. Intranasal insulin improves memory in humans. Psychoneuroendocrinology2004; 29: 1326–34.
58. G.R.SridharG.LakshmiG.Nagamani. Emerging links between type 2 diabetes and Alzheimer's disease. World J Diab2015; 6: 744–51.
59. C.BenedictM.HallschmidA.HatkeB.SchultesH.L.FehmJ.BornW.Kern. Intranasal insulin improves memory in humans. Psychoneuroendocrinology2004; 29: 1326–34.
60. T.S.SalamehK.M.BullockI.A.HujoelM.L.NiehoffT.Wolden-HansonJ.KimJ.E.MorleyS.A.FarrW.A.Banks. Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition. J Alzheimers Dis2015; 47: 715–28.
61. Y.ChenY.ZhaoC.-L.DaiZ.LiangX.RunK.IqbalF.LiuC.-X.Gong. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice. Exp Neurol2014; 261: 610–9.
62. W.A.BanksJ.B.OwenM.A.Erickson. Insulin in the brain: there and back again. Pharmacol Therapeut2012; 136: 82–93.
63. T.MatsuzakiK.SasakiY.TanizakiJ.HataK.FujimiY.MatsuiA.SekitaS.O.SuzukiS.KanbaY.KiyoharaT.Iwaki. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology2010; 75: 764–70.
64. S.TakedaN.SatoK.Uchio-YamadaH.YuA.MoriguchiH.RakugiR.Morishita. Oral glucose loading modulates plasma beta-amyloid level in alzheimer's disease patients: potential diagnostic method for Alzheimer's disease. Dement Geriatr Cogn Disord2012; 34: 25–30.
65. R.TakechiS.GallowayM.M.Pallebage-GamarallageV.LamJ.C.Mamo. Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog Lipid Res2010; 49: 159–70.
66. J.DumurgierC.PaquetK.Peoc'hP.LapalusF.Mouton-LigerS.BenistyS.ChasseigneauxH.ChabriatJ.Hugon. CSF Abeta1-42 levels and glucose metabolism in Alzheimer's Disease. J Alzheimers Dis2011; 27: 845–51.
67. M.A.RegerG.S.WatsonP.S.GreenL.D.BakerB.CholertonM.A.FishelS.R.PlymateM.M.CherrierG.D.SchellenbergW.H.Frey2ndS.Craft. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis2008; 13: 323–31.
68. A.ClaxtonL.D.BakerC.W.WilkinsonE.H.TrittschuhD.ChapmanaG.S.WatsonB.CholertonS.R.PlymateM.ArbuckleS.Craft. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J Alzheimers Dis2013; 35: 789–97.
69. M.H.RosenbloomT.R.BarclayM.PyleB.L.OwensA.B.CaganC.P.AndersonW.H.FreyL.R.Hanson. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. CNS Drugs2014; 28: 1185–9.
70. A.ClaxtonL.D.BakerA.HansonE.H.TrittschuhB.CholertonA.MorganM.CallaghanM.ArbuckleC.BehlS.Craft. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis2014; 44: 897–906.
71. S.CraftS.AsthanaG.SchellenbergL.BakerM.CherrierA.A.BoytR.N.MartinsM.RaskindE.PeskindS.Plymate. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci2000; 903: 222–8.
72. A.J.HansonJ.L.BayerL.D.BakerB.CholertonB.VanFossenE.TrittschuhR.A.RissmanM.C.DonohueS.H.MoghadamS.R.PlymateS.Craft. Differential effects of meal challenges on cognition, metabolism, and biomarkers for apolipoprotein E varepsilon4 carriers and adults with mild cognitive impairment. J Alzheimers Dis2015; 48: 205–18.
73. B.L.WanamakerK.J.SwigerR.S.BlumenthalS.S.Martin. Cholesterol, statins, and dementia: what the cardiologist should know. Clin Cardiol2015; 38: 243–50.
74. J.H.Moon. Endocrine risk factors for cognitive impairment. Endocrinol Metab2016; 31: 185–92.
75. R.CreeganW.HuntA.McManusS.R.Rainey-Smith. Diet, nutrients and metabolism: cogs in the wheel driving Alzheimer's disease pathology?Br J Nutr2015; 113: 1499–517.
76. P.Foley. Lipids in Alzheimer's disease: a century-old story. Biochim Biophys Acta2010; 1801: 750–3.
77. J.A.LuchsingerR.Mayeux. Dietary factors and Alzheimer's disease. Lancet Neurol2004; 3: 579–87.
78. W.L.LimI.J.MartinsR.N.Martins. The involvement of lipids in Alzheimer's disease. J Genet Genom2014; 41: 261–74.
79. G.Di PaoloT.W.Kim. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci2011; 12: 284–96.
80. J.RubinL.Berglund. Apolipoprotein E and diets: a case of gene-nutrient interaction?Curr Opin Lipidol2002; 13: 25–32.
81. S.E.KanoskiR.L.MeiselA.J.MullinsT.L.Davidson. The effects of energy-rich diets on discrimination reversal learning and on BDNF in the hippocampus and prefrontal cortex of the rat. Behav Brain Res2007; 182: 57–66.
82. M.MaesakoM.UemuraY.TashiroK.SasakiK.WatanabeY.NodaK.UedaM.Asada-UtsugiM.KubotaK.OkawaM.IharaS.ShimohamaK.UemuraA.Kinoshita. High fat diet enhances beta-site cleavage of amyloid precursor protein (APP) via promoting beta-site APP cleaving enzyme 1/adaptor protein 2/clathrin complex formation. PLoS One2015; 10: e0131199–e0131199.
83. J.A.HardyG.A.Higgins. Alzheimer's disease: the amyloid cascade hypothesis. Science1992; 256: 184–5.
84. W.A.BanksA.B.CoonS.M.RobinsonA.MoinuddinJ.M.ShultzR.NakaokeJ.E.Morley. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes2004; 53: 1253–60.
85. A.UrayamaW.A.Banks. Starvation and triglycerides reverse the obesity-induced impairment of insulin transport at the blood-brain barrier. Endocrinology2008; 149: 3592–7.
86. W.A.BanksB.O.BurneyS.M.Robinson. Effects of triglycerides, obesity, and starvation on ghrelin transport across the blood-brain barrier. Peptides2008; 29: 2061–5.
87. S.DianoS.A.FarrS.C.BenoitE.C.McNayI.da SilvaB.HorvathF.S.GaskinN.NonakaL.B.JaegerW.A.BanksJ.E.MorleyS.PintoR.S.SherwinL.XuK.A.YamadaM.W.SleemanM.H.TschopT.L.Horvath. Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci2006; 9: 381–8.
88. M.DurakoglugilA.J.IrvingJ.Harvey. Leptin induces a novel form of NMDA receptor-dependent long-term depression. J Neurochem2005; 95: 396–405.
89. L.J.ShanleyA.J.IrvingJ.Harvey. Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J Neurosc2001; 21: RC186–RC186.
90. M.J.JaneT.H.WilliamW.F.DavidJ.G.StevenP.GeorgeJ.M.ThomasQ.T.JohnM.S.LeslieJ.W.AshfordT.Nikolaos. Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res2014; 11: 165–74.
91. J.M.JohnstonS.J.GrecoA.HamzelouJ.W.AshfordN.Tezapsidis. Repositioning leptin as a therapy for Alzheimer's disease. Therapy2011; 8: 481–90.
92. G.-Q.ChangO.KaratayevZ.DavydovaS.F.Leibowitz. Circulating triglycerides impact on orexigenic peptides and neuronal activity in hypothalamus. Endocrinology2004; 145: 3904–12.
93. K.E.WortleyG.-Q.ChangZ.DavydovaS.F.Leibowitz. Orexin gene expression is increased during states of hypertriglyceridemia. Am J Physiol Regul Integr Comp Physiol2003; 284: R1454–65.
94. C.C.WelchE.-M.KimM.K.GraceC.J.BillingtonA.S.Levine. Palatability-induced hyperphagia increases hypothalamic dynorphin peptide and mRNA levels. Brain Res1996; 721: 126–31.
95. Y.OomuraT.NakamuraM.SugimoriY.Yamada. Effect of free fatty acid on the rat lateral hypothalamic neurons. Physiol Behav1975; 14: 483–6.
96. L.ShenK.CareyD.Q.H.WangS.C.WoodsM.Liu. Food-entrained rhythmic expression of apolipoprotein E expression in the hypothalamus of rats. Brain Res2009; 1273: 66–71.
97. Z.A.CordnerK.L.K.Tamashiro. Effects of high-fat diet exposure on learning & memory. Physiol Behav2015; 152(Part B): 363–71.
98. J.E.Morley. The metabolic syndrome and aging. J Gerontol A Biol Sci Med Sci2004; 59: M139–M42.
99. S.A.FarrK.A.YamadaD.A.ButterfieldH.M.AbdulL.XuN.E.MillerW.A.BanksJ.E.Morley. Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology2008; 149: 2628–36.
100. L.A.JohnsonK.L.ZuloagaT.L.KugelmanK.S.MaderJ.T.MorréD.G.ZuloagaS.WeberT.MarzullaA.MulfordD.ButtonJ.R.LindnerN.J.AlkayedJ.F.StevensJ.Raber. Amelioration of metabolic syndrome-associated cognitive impairments in mice via a reduction in dietary fat content or infusion of non-diabetic plasma. EBioMedicine2015; 3: 26–42.
101. A.J.HansonJ.L.Bayer-CarterP.S.GreenT.J.MontineC.W.WilkinsonL.D.BakerG.S.WatsonL.M.BonnerM.CallaghanJ.B.LeverenzE.TsaiN.PostupnaJ.ZhangJ.LampeS.Craft. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol2013; 70: 972–80.
102. T.L.HuangP.P.ZandiK.L.TuckerA.L.FitzpatrickL.H.KullerL.P.FriedG.L.BurkeM.C.Carlson. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology2005; 65: 1409–14.
103. P.Barberger-GateauC.SamieriC.FeartM.Plourde. Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype. Curr Alzheimer Res2011; 8: 479–91.
104. S.T.Henderson. High carbohydrate diets and Alzheimer's disease. Med Hypotheses2004; 62: 689–700.
105. S.T.HendersonJ.Poirier. Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled study. BMC Med Genet2011; 12: 137–137.
106. M.A.RegerS.Craft. Intranasal insulin administration: a method for dissociating central and peripheral effects of insulin. Drugs Today2006; 42: 729–39.